Core Insights - Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, enhancing its expertise in oncology drug development as it advances its lead candidate AKTX-101 toward clinical trials [1][2][4] Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing, differentiating it from conventional ADCs that use tubulin inhibitors or DNA-damaging agents [7] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, indicating prolonged survival compared to traditional ADCs [7] - The company is also developing AKTX-102, which targets CEACAM5, a tumor antigen expressed across multiple solid tumors, leveraging the same PH1 payload for enhanced therapeutic effects [7] Dr. Prafulla Gokhale's Role - Dr. Gokhale brings over 20 years of experience in preclinical oncology drug discovery and development, having previously led pharmacology teams at major pharmaceutical companies [4] - His expertise in experimental therapeutics and translational oncology is expected to strengthen Akari's clinical strategies for AKTX-101, ensuring a data-driven approach as the company prepares for first-in-human studies [2][6] Mechanism of Action - The PH1 payload is designed to modulate spliceosomes, disrupting RNA splicing within cancer cells, which has been shown to induce cancer cell death while engaging both innate and adaptive immune responses [5][7] - Preclinical models indicate that AKTX-101 may work synergistically with checkpoint inhibitors, enhancing its therapeutic potential [7]

Core Insights - Akari Therapeutics is set to present at the 2026 Biocom Global Partnering & Investor Conference, highlighting its focus on oncology biotechnology and antibody drug conjugates (ADCs) with novel immuno-oncology payloads [1][2]. Company Overview - Akari Therapeutics specializes in developing next-generation ADCs, particularly focusing on a unique payload, PH1, which targets RNA splicing [3]. - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [3]. - PH1 is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing potential to induce cancer cell death while activating both innate and adaptive immune responses [3]. - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy when combined with checkpoint inhibitors [3]. - The company has initiated IND enabling studies for AKTX-101, aiming to start its First-In-Human trial by late 2026 or early 2027 [3]. - Akari is also developing AKTX-102, targeting CEACAM5, a tumor antigen expressed in various solid tumors, leveraging the PH1 payload for enhanced tumor cell killing and immune activation [3].

Core Insights - Akari Therapeutics is expanding its antibody drug conjugate (ADC) pipeline and intellectual property strategy, as discussed by CEO Abizer Gaslightwala in a recent virtual investor interview [2][4] - The company is advancing its lead ADC program, AKTX-101, towards Investigational New Drug (IND) and Clinical Trial Application (CTA) submissions, aiming for first-in-human studies by late 2026 or early 2027 [4][6] ADC Pipeline Expansion - Akari has introduced AKTX-102, its second ADC candidate targeting CEACAM5-expressing solid tumors, highlighting the scalability of its PH1-powered ADC platform [3][4] - The company’s differentiated approach to CEACAM5 involves a novel antibody construct combined with the PH1 spliceosome-modulating payload [4] Intellectual Property Strategy - The recent patent filing is a significant milestone that supports Akari's long-term value creation and potential partnering opportunities [3][4] - The growing patent estate is strategically important for the company as it seeks to enhance its market position and protect its innovations [4] Lead Program Details - AKTX-101 targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [6] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy with checkpoint inhibitors [6]